Affiliated Focus Groups

Computational Drug Design
Dermatopharmaceutics
Excipients
Inhalation and Nasal Technology
Intellectual Property
Lipid-Based Drug Delivery Systems
Modified Release
Nanotechnology
Oral Absorption
Preformulation
Prodrug

Physical Pharmacy and Biopharmaceutics

The Physical Pharmacy and Biopharmaceutics (PPB) Section is composed of AAPS members whose scientific interests are in the physicochemical and biological factors that impact the design and delivery of small molecules and biologics. PPB is a multidisciplinary section that focuses on preformulation, biopharmaceutics, drug absorption, nanotechnology, and drug delivery systems design and performance including targeted drug delivery. PPB provides an interactive forum for the exchange of information pertaining to the selection of developable drug candidates at the drug discovery-development interface, characterization of drug substance and excipients, studies of relationships between drugs’ physicochemical and biopharmaceutical properties and physiological considerations at the cellular, organ, and whole animal levels, and overcoming drug absorption and delivery barriers via drug delivery technologies.

PPB Section Vision

The PPB Section will be recognized as the premiere global organization for scientists involved in physicochemical and biopharmaceutical characterization and delivery of small molecules and biologics.

PPB Section Mission

The PPB section strives to advance physical pharmacy and biopharmaceutics by:

• providing a forum for the open interchange, discussion and dissemination of emerging scientific developments, technologies, and regulatory knowledge regarding the principles and practices of physical pharmacy and biopharmaceutics;
• promoting the continued growth and development of the sciences underpinning physicochemical and biopharmaceutic characterization of small molecules and biologics, pharmaceutical excipients and adjuvants, drug candidate selection, drug transport and absorption, preformulation, and biopharmaceutic data guiding the formulation and drug delivery strategies;
• fostering pharmaceutical education, career growth, and professional development of the section membership;
• encouraging the publication of physical pharmacy and biopharmaceutics related research and data in AAPS publications;
• recognizing excellence in achievements and professional contributions of PPB members; and
• collaborating with and supporting other AAPS sections, focus groups, and international professional/scientific organizations.

PPB By-Laws

Please check back frequently for more information about the brand new PPB Section!

The archived websites for the Pharmaceutics and Drug Delivery (PDD) Section and the
Pharmaceutical Technologies (PT) Section are still available for access.

Chair
Lawrence X. Yu, Ph.D.

North Potomac, MD UNITED STATES

Chair-Elect
Michael J. Hageman, Ph.D.
Bristol-Myers Squibb
Princeton, NJ UNITED STATES

Vice Chair
Duxin Sun, Ph.D.
University of Michigan
Ann Arbor, MI UNITED STATES

Secretary/Treasurer
Tycho H. Heimbach, Ph.D.
Novartis Pharmaceuticals Corporation
East Hanover, NJ UNITED STATES

Annual Meeting Screeners Committee
Nathalie Y. Toussaint, Ph.D.
Bristol-Myers Squibb
Princeton, NJ United States

Annual Meeting Program Committee
Michael J. Hageman, Ph.D.
Bristol-Myers Squibb
Princeton, NJ UNITED STATES

Content Advisory Cmte
Naushad M. Khan Ghilzai, Ph.D.
LECOM School of Pharmacy
Erie, PA United States

Student/Postdoc Committee
AYMAN FAWZI EL-KATTAN, Ph.D
Pfizer Inc.
Groton, CT

Fellows Committee
Gregory E. Amidon, Ph.D.
University of Michigan
Ann Arbor, MI United States

Nominations Committee
Lawrence X. Yu, Ph.D.

North Potomac, MD UNITED STATES

Program Coordination Committee
Michael J. Hageman, Ph.D.
Bristol-Myers Squibb
Princeton, NJ UNITED STATES

Communications Committee
Balvinder S. Vig, Ph.D
Bristol Myers Squibb
New Brunswick, NJ UNITED STATES

Webmasters Committee
Sherry M. Ku
Wyeth Research
Pearl River, NY

Member Strategic Oversight Committee
Pei Fan Bai, Ph.D.
FDA
Silver Spring, MD

Executive Council Liaison
Patrick J. McNamara, Ph.D.
University of Kentucky
Lexington, KY UNITED STATES

Staff Liaison
Peter Inchauteguiz
AAPS
Arlington, VA UNITED STATES

Excipients Focus Group
Brian AC Carlin, Ph.D.
FMC BioPolymer
Princeton, NJ

Computational Drug Design Focus Group
Prof. Chang-Guo Zhan
University of Kentucky
Lexington, KY UNITED STATES

Inhalation & Nasal Technology Focus Group
Jill K. Sherwood
N/A
Southington, CT United States

Intellectual Property Focus Group
Eyal H. Barash, J.D.
SSCI Inc
West Lafayette, IN UNITED STATES

Lipid-Based Drug Delivery Systems Focus Group
Panayiotis P. Constantinides, Ph.D.
Biopharmaceutical and Drug Delivery Consulting, LLC
Gurnee, IL UNITED STATES

Microdialysis Focus Group
Dr. Grazia Stagni
Long Island University
Brooklyn, NY UNITED STATES

Modified Release Focus Group
John R. Crison, Ph.D.
Simulations Plus
Lancaster, CA UNITED STATES

Nanotechnology Focus Group
Patrick J. Sinko, Ph.D.
Rutgers University College of Pharmacy
Piscataway, NJ UNITED STATES

Ocular Drug Delivery & Disposition Focus Group
Dr. Brian R. Rohrs
Bausch & Lomb
Rochester, NY UNITED STATES

Oral Absorption Focus Group
Dr. Praveen V. Balimane
Bristol-Myers Squibb
Princeton, NJ United States

Preformulation Focus Group
Tapan K. Das, Ph.D.
Pfizer, St. Louis
Chesterfield, MO United States

Preformulation Focus Group
Eric J. Munson, Ph.D
University of Kansas
Lawrence, KS

Prodrug Focus Group
Duxin Sun, Ph.D.
University of Michigan
Ann Arbor, MI UNITED STATES